These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9561680)

  • 1. Lipid abnormalities in stable liver transplant recipients--effects of cyclosporin, tacrolimus, and steroids.
    Fernández-Miranda C; Guijarro C; de la Calle A; Loinaz C; Gonzalez-Pinto I; Gómez-Izquierdo T; Larumbe S; Moreno E; del Palacio A
    Transpl Int; 1998; 11(2):137-42. PubMed ID: 9561680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus.
    Taylor DO; Barr ML; Radovancevic B; Renlund DG; Mentzer RM; Smart FW; Tolman DE; Frazier OH; Young JB; VanVeldhuisen P
    J Heart Lung Transplant; 1999 Apr; 18(4):336-45. PubMed ID: 10226898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid profiles in pediatric thoracic transplant recipients are determined by their immunosuppressive regimens.
    Law YM; Yim R; Agatisa P; Boyle GJ; Miller SA; Lawrence K; Webber SA
    J Heart Lung Transplant; 2006 Mar; 25(3):276-82. PubMed ID: 16507419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppression enhances atherogenicity of lipid profile after transplantation.
    Quaschning T; Mainka T; Nauck M; Rump LC; Wanner C; Krämer-Guth A
    Kidney Int Suppl; 1999 Jul; 71():S235-7. PubMed ID: 10412786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study.
    McCune TR; Thacker LR II; Peters TG; Mulloy L; Rohr MS; Adams PA; Yium J; Light JA; Pruett T; Gaber AO; Selman SH; Jonsson J; Hayes JM; Wright FH; Armata T; Blanton J; Burdick JF
    Transplantation; 1998 Jan; 65(1):87-92. PubMed ID: 9448150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of changing immunosuppressive monotherapy from Cyclosporin A to Tacrolimus in long-term, stable liver transplant recipients.
    Ott R; Bussenius-Kammerer M; Reck T; Koch CA; Kissler H; Hohenberger W; Müller V
    Transpl Int; 2004 Jan; 17(1):39-43. PubMed ID: 14504723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus-based triple-drug immunosuppression minimizes serum lipid elevations in pediatric cardiac transplant recipients.
    Penson MG; Winter WE; Fricker FJ; Harker K; Kahler DA; Kubilis PS; Schowengerdt KO
    J Heart Lung Transplant; 1999 Jul; 18(7):707-13. PubMed ID: 10452348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion.
    White M; Haddad H; Leblanc MH; Giannetti N; Pflugfelder P; Davies R; Isaac D; Burton J; Chan M; Azevedo E; Howlett J; Ignaszewski A; Busque S; Cantarovich M; Ferguson R; Genest J; Ross H
    J Heart Lung Transplant; 2005 Jul; 24(7):798-809. PubMed ID: 15982605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum cholesterol changes in long-term survivors of liver transplantation: a comparison between cyclosporine and tacrolimus therapy.
    Charco R; Cantarell C; Vargas V; Capdevila L; Lázaro JL; Hidalgo E; Murio E; Margarit C
    Liver Transpl Surg; 1999 May; 5(3):204-8. PubMed ID: 10226111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients.
    Penson MG; Fricker FJ; Thompson JR; Harker K; Williams BJ; Kahler DA; Schowengerdt KO
    J Heart Lung Transplant; 2001 Jun; 20(6):611-8. PubMed ID: 11404165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus.
    Trotter JF; Wachs ME; Trouillot TE; Bak T; Kugelmas M; Kam I; Everson G
    Liver Transpl; 2001 May; 7(5):401-8. PubMed ID: 11349259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of serum atherogenic risk in liver transplant recipients: Role of lipoproteins and metabolic and inflammatory markers.
    Chhatrala R; Siddiqui MB; Stravitz RT; Driscoll C; Sanyal A; Sargeant C; Luketic V; Sharma A; Sterling R; Matherly S; Puri P; Siddiqui MS
    Liver Transpl; 2015 May; 21(5):623-30. PubMed ID: 25762084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus.
    Ichimaru N; Takahara S; Kokado Y; Wang JD; Hatori M; Kameoka H; Inoue T; Okuyama A
    Atherosclerosis; 2001 Oct; 158(2):417-23. PubMed ID: 11583721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of oral fructose load on serum uric acid and lipids in kidney transplant recipients treated with cyclosporine or tacrolimus.
    Zawiasa A; Szklarek-Kubicka M; Fijałkowska-Morawska J; Nowak D; Rysz J; Mamełka B; Nowicki M
    Transplant Proc; 2009; 41(1):188-91. PubMed ID: 19249511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of fluvastatin on hyperlipidemia after renal transplantation: influence of steroid therapy.
    Austen JL; Shifrin FA; Bartucci MR; Knauss TC; Schulak JA; Hricik DE
    Ann Pharmacother; 1996 Dec; 30(12):1386-9. PubMed ID: 8968448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus.
    Friemann S; Feuring E; Padberg W; Ernst W
    Transplant Proc; 1998 Jun; 30(4):1240-2. PubMed ID: 9636504
    [No Abstract]   [Full Text] [Related]  

  • 17. Lipoprotein abnormalities in long-term stable liver and renal transplanted patients. A comparative study.
    Fernández-Miranda C; de la Calle A; Morales JM; Guijarro C; Aranda JL; Gómez-Sanz R; Gómez-Izquierdo T; Larumbe S; Moreno E; Rodicio JL; del Palacio A
    Clin Transplant; 1998 Apr; 12(2):136-41. PubMed ID: 9575402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients.
    Manzarbeitia C; Reich DJ; Rothstein KD; Braitman LE; Levin S; Munoz SJ
    Liver Transpl; 2001 Feb; 7(2):93-9. PubMed ID: 11172391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of cyclosporin A and FK 506 on lipid metabolism and fibrinogen in kidney transplant recipients.
    Hohage H; Arlt M; Brückner D; Dietl KH; Zidek W; Spieker C
    Clin Transplant; 1997 Jun; 11(3):225-30. PubMed ID: 9193847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of cyclosporin and tacrolimus on lipoprotein oxidation after renal transplantation].
    Martínez Castelao A; Ramos R; Serón D; Gil-Vernet S; Fiol C; Gómez-Gerique N; Yzaguirre MT; Hurtado I; Sabaté I; Alsina J; Grinyó JM
    Nefrologia; 2002; 22(4):364-9. PubMed ID: 12369128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.